In a clinic in Wuhan, researchers just changed the way doctors can see kidney cancer. A patient four years after surgery showed up for routine follow-up, and a new PET scanner called 68Ga-RCC78 did something traditional imaging couldn't: it lit up metastatic tumors hiding in the mediastinum, pancreas, adrenal gland, and kidney with such clarity that the uptake values exceeded 30 on the standard measurement scale. Those lesions had been invisible before. This isn't incremental progress—it's the difference between finding cancer and missing it entirely.
Clear cell renal cell carcinoma, or ccRCC, kills thousands annually and often spreads silently. The disease has a molecular signature that researchers have known about for years: tumors overexpress a protein called carbonic anhydrase IX, or CAIX. The problem was that the body also naturally produces CAIX in the gastrointestinal tract, creating a blinding fog of background noise on traditional CAIX-targeting scans. Any metastases hiding in the abdomen simply disappeared into the static. For decades, this physiological barrier made CAIX an attractive but frustratingly difficult imaging target.
Dr. Sixuan Cheng and colleagues at Union Hospital, Tongji Medical College, and Huazhong University of Science and Technology in Wuhan took a different approach. Instead of using traditional antibody-based tracers that take days to clear the body, they designed 16 novel cyclic peptide probes, radiolabeling them with the isotope 68Ga. Among these candidates, 68Ga-RCC78 emerged as the winner: it achieved high-contrast tumor visualization rapidly while keeping intestinal background minimal—a balance that had eluded earlier designs.
The evidence was rigorous. In mice bearing CAIX-high tumors, 68Ga-RCC78 showed sustained high uptake in cancer cells with rapid clearance everywhere else. When tested in 13 kidney cancer patients, the tracer accurately distinguished CAIX-positive tumors from CAIX-negative ones, confirming results with biopsy immunostaining. For CAIX-positive cases, the primary and metastatic tumor uptake markedly exceeded what the standard tracer, 18F-FDG, could achieve. Most importantly, the low intestinal activity meant doctors could finally see intra-abdominal and metastatic lesions clearly.
"This research provides a more precise molecular map for kidney cancer," said Dr. Dawei Jiang, professor and deputy director of the Nuclear Medicine Department at Wuhan Union Hospital. But Jiang and his team are thinking beyond diagnosis. The same molecular design is now being labeled with therapeutic isotopes to deliver targeted radiation directly to cancer cells while sparing healthy tissue—a strategy known as theranostics, where one molecule both diagnoses and treats disease in personalized ways.
The research was presented at the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, and remains in early clinical evaluation. Access through specialized clinical trials could become possible within one to two years, with broader availability depending on regulatory approval. For kidney cancer patients who have faced the uncertainty of undetected metastases, and for doctors eager for sharper diagnostic tools, this tracer represents genuine hope—a molecular innovation that cuts through the noise and reveals disease where it hides.